Hepatitis B innovative therapy! Geli subcutaneous injection of PD-L1 antibody asc22 was approved by the State Food and drug administration, and clinical trials were carried out in patients with chronic hepatitis B!

January 24, 2020 / BIOON / -- ascletis recently announced that its subcutaneous injection of PD-L1 antibody asc22 has been approved by China National Drug Administration (nmpa) to carry out clinical trials in patients with chronic hepatitis B Asc22 is the world's first in class subcutaneous injection of PD-L1 antibody approved for clinical trials in patients with chronic hepatitis B According to the global hepatitis report 2017 released by who, the number of people infected with hepatitis B virus worldwide is about 257 million, and the number of people infected in China is more than 86 million In chronic hepatitis B virus infection, T cell depletion is an important factor of immune tolerance, and blocking PD-1 / PD-L1 pathway can effectively improve the specific killing T cell function, which is expected to achieve clinical cure in patients with chronic hepatitis B In addition to asc22, Geli's chronic hepatitis B product pipeline also includes three other products: palosine ® which has been put on the market and two other products under research and development, which are currently in the pre ind stage and about to declare ind stage respectively "We are very excited that asc22 has been approved to carry out clinical trials in patients with chronic hepatitis B," said Dr Wu JINZI, founder, chairman and CEO of Geli As a first-in-class immune drug that is expected to cure chronic hepatitis B clinically, asc22 can become the cornerstone drug in a series of clinical treatment schemes in the future Through the combination of the candidate drugs developed by us or with the candidate drugs of other leading enterprises in the industry, it is expected to overcome the clinical cure problem of hepatitis B in the future " Asc22 (kn035) is a PD-L1 monoclonal antibody which can be used for subcutaneous injection It has the advantages of subcutaneous injection and stability at room temperature, so as to improve patients' drug compliance and quality of life It is of great value to achieve the goal of long-term management of chronic diseases such as chronic hepatitis B On January 14, 2019, Geli and Suzhou Corning Jerry Biotechnology Co., Ltd signed a strategic cooperation agreement in the field of hepatitis B and other viral diseases Geli is an innovative R & D driven biotechnology company with two listed products, which has been listed on the Hong Kong stock exchange Geli focuses on the field of liver disease and is committed to the development of innovative drugs related to liver disease to meet the needs of patients at home and abroad Under the leadership of a management team with profound professional knowledge and outstanding past achievements, Geli has developed into an integrated platform company, covering the entire value chain from new drug discovery and development to production and commercialization Geli's products under research and on the market are mainly focused on the following three areas: 1 Hepatitis C: three products under research and one product on the market (the first direct antiviral drug for hepatitis C treatment developed by local enterprises in China, gonovi ®) 2 In the field of hepatitis B: three products under development and one product already on the market (long-term interferon paroxin ® with good market basis, which is used for hepatitis B and hepatitis C treatment in cooperation with Roche) 3 Nonalcoholic steatohepatitis (NASH): three products under development Original source: Geli biology